 Stephen Dreskin
Concepts (463)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peanut Hypersensitivity | 26 | 2023 | 204 | 7.120 |
Why?
| | Immunoglobulin E | 40 | 2023 | 365 | 6.150 |
Why?
| | Antigens, Plant | 22 | 2023 | 53 | 5.690 |
Why?
| | Allergens | 23 | 2023 | 424 | 5.560 |
Why?
| | 2S Albumins, Plant | 19 | 2023 | 29 | 5.500 |
Why?
| | Arachis | 19 | 2023 | 152 | 4.560 |
Why?
| | Glycoproteins | 12 | 2016 | 319 | 3.110 |
Why?
| | Urticaria | 11 | 2018 | 51 | 2.810 |
Why?
| | Epitopes | 8 | 2023 | 443 | 1.960 |
Why?
| | Mast Cells | 13 | 2021 | 115 | 1.760 |
Why?
| | Basophils | 14 | 2018 | 66 | 1.640 |
Why?
| | Desensitization, Immunologic | 3 | 2019 | 113 | 1.150 |
Why?
| | Benzoquinones | 4 | 2007 | 44 | 0.900 |
Why?
| | Food Hypersensitivity | 3 | 2020 | 260 | 0.870 |
Why?
| | Nuts | 2 | 2023 | 12 | 0.830 |
Why?
| | Anti-Allergic Agents | 3 | 2018 | 41 | 0.770 |
Why?
| | Receptors, IgE | 11 | 2003 | 40 | 0.760 |
Why?
| | Omalizumab | 2 | 2018 | 45 | 0.750 |
Why?
| | Seeds | 1 | 2020 | 76 | 0.750 |
Why?
| | Plant Proteins | 6 | 2023 | 81 | 0.740 |
Why?
| | Peptide Library | 2 | 2017 | 80 | 0.720 |
Why?
| | Amino Acids | 1 | 2023 | 465 | 0.720 |
Why?
| | Peptide Mapping | 1 | 2019 | 63 | 0.710 |
Why?
| | Anaphylaxis | 3 | 2018 | 146 | 0.710 |
Why?
| | Allergists | 1 | 2018 | 19 | 0.660 |
Why?
| | Protein Conformation | 5 | 2022 | 848 | 0.650 |
Why?
| | Immunoglobulin G | 7 | 2022 | 788 | 0.620 |
Why?
| | Allergy and Immunology | 1 | 2018 | 57 | 0.620 |
Why?
| | Rhinitis, Allergic, Seasonal | 3 | 2008 | 32 | 0.600 |
Why?
| | Plant Extracts | 3 | 2018 | 165 | 0.600 |
Why?
| | Bortezomib | 1 | 2016 | 42 | 0.580 |
Why?
| | Anti-Inflammatory Agents | 4 | 2008 | 465 | 0.560 |
Why?
| | Drug Hypersensitivity | 2 | 2013 | 83 | 0.550 |
Why?
| | Interleukin-5 | 2 | 2008 | 31 | 0.540 |
Why?
| | Antibodies, Anti-Idiotypic | 2 | 2014 | 56 | 0.540 |
Why?
| | Amino Acid Sequence | 7 | 2023 | 2071 | 0.530 |
Why?
| | Hypersensitivity, Immediate | 4 | 2013 | 59 | 0.510 |
Why?
| | Proteome | 1 | 2018 | 353 | 0.500 |
Why?
| | Models, Molecular | 2 | 2016 | 1435 | 0.480 |
Why?
| | Peptides | 6 | 2023 | 879 | 0.480 |
Why?
| | Humans | 69 | 2023 | 118974 | 0.470 |
Why?
| | Animals | 33 | 2022 | 33381 | 0.470 |
Why?
| | Cell Degranulation | 3 | 2014 | 38 | 0.460 |
Why?
| | Cross Reactions | 4 | 2023 | 116 | 0.440 |
Why?
| | Pharmacy Service, Hospital | 1 | 2013 | 86 | 0.420 |
Why?
| | Clinical Protocols | 1 | 2013 | 238 | 0.410 |
Why?
| | Autoimmunity | 3 | 2013 | 831 | 0.410 |
Why?
| | Autoimmune Diseases | 2 | 2013 | 398 | 0.410 |
Why?
| | Compensation and Redress | 1 | 2011 | 7 | 0.400 |
Why?
| | National Health Programs | 1 | 2011 | 21 | 0.400 |
Why?
| | Protein Binding | 5 | 2019 | 1975 | 0.390 |
Why?
| | B-Lymphocytes | 1 | 2016 | 770 | 0.390 |
Why?
| | Phosphatidylinositols | 6 | 1995 | 52 | 0.380 |
Why?
| | Influenza Vaccines | 3 | 2013 | 500 | 0.380 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2010 | 88 | 0.370 |
Why?
| | Leukemia, Basophilic, Acute | 5 | 1995 | 5 | 0.370 |
Why?
| | Rats | 16 | 2015 | 5392 | 0.370 |
Why?
| | Hydroxyproline | 2 | 2023 | 24 | 0.370 |
Why?
| | HLA-DR Antigens | 1 | 2010 | 224 | 0.350 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 667 | 0.350 |
Why?
| | Immune Tolerance | 1 | 2011 | 334 | 0.350 |
Why?
| | Thyroid Gland | 2 | 2009 | 84 | 0.340 |
Why?
| | Chronic Disease | 8 | 2018 | 1636 | 0.340 |
Why?
| | Antibodies | 1 | 2011 | 392 | 0.340 |
Why?
| | Type C Phospholipases | 5 | 1995 | 66 | 0.330 |
Why?
| | Eosinophils | 2 | 2021 | 282 | 0.330 |
Why?
| | Thimerosal | 1 | 2007 | 4 | 0.320 |
Why?
| | Phagocyte Bactericidal Dysfunction | 4 | 1987 | 12 | 0.300 |
Why?
| | Job Syndrome | 4 | 1987 | 5 | 0.300 |
Why?
| | Disease Models, Animal | 7 | 2018 | 3730 | 0.300 |
Why?
| | Bone Marrow Cells | 2 | 2016 | 273 | 0.290 |
Why?
| | Receptors, Fc | 4 | 1991 | 48 | 0.280 |
Why?
| | HLA-D Antigens | 1 | 2006 | 36 | 0.280 |
Why?
| | Leukotrienes | 1 | 2006 | 35 | 0.280 |
Why?
| | Respiratory Hypersensitivity | 1 | 2006 | 65 | 0.270 |
Why?
| | Epitope Mapping | 2 | 2016 | 49 | 0.270 |
Why?
| | RNA, Messenger | 4 | 2007 | 2657 | 0.270 |
Why?
| | Angioedema | 2 | 2010 | 17 | 0.270 |
Why?
| | Vaccination | 2 | 2011 | 1222 | 0.260 |
Why?
| | Cell Line | 8 | 2019 | 2707 | 0.260 |
Why?
| | Isoenzymes | 2 | 2003 | 297 | 0.260 |
Why?
| | Hypersensitivity | 3 | 2008 | 268 | 0.260 |
Why?
| | Transcriptional Activation | 1 | 2007 | 348 | 0.250 |
Why?
| | Adenosine Triphosphate | 4 | 1995 | 439 | 0.250 |
Why?
| | Tumor Cells, Cultured | 8 | 2003 | 874 | 0.250 |
Why?
| | Interferon-gamma | 1 | 2008 | 736 | 0.250 |
Why?
| | Molecular Sequence Data | 6 | 2015 | 2871 | 0.250 |
Why?
| | Down-Regulation | 2 | 2006 | 627 | 0.240 |
Why?
| | Hospitalization | 1 | 2013 | 1785 | 0.240 |
Why?
| | Skin Tests | 4 | 2013 | 135 | 0.240 |
Why?
| | Cell Nucleus | 1 | 2007 | 580 | 0.230 |
Why?
| | Anti-Bacterial Agents | 1 | 2013 | 1510 | 0.230 |
Why?
| | Alanine | 1 | 2023 | 102 | 0.230 |
Why?
| | Anacardium | 1 | 2023 | 1 | 0.230 |
Why?
| | Pistacia | 1 | 2023 | 2 | 0.230 |
Why?
| | Juglans | 1 | 2023 | 7 | 0.230 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2003 | 72 | 0.230 |
Why?
| | NF-kappa B | 1 | 2007 | 670 | 0.220 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 2062 | 0.220 |
Why?
| | Hypergammaglobulinemia | 3 | 1987 | 9 | 0.220 |
Why?
| | Child, Preschool | 8 | 2019 | 9491 | 0.210 |
Why?
| | Mice | 9 | 2022 | 15520 | 0.210 |
Why?
| | Arachidonate 5-Lipoxygenase | 2 | 2006 | 45 | 0.210 |
Why?
| | Bone Marrow | 3 | 2021 | 255 | 0.210 |
Why?
| | Nasal Mucosa | 1 | 2002 | 97 | 0.210 |
Why?
| | Basophil Degranulation Test | 3 | 2012 | 7 | 0.210 |
Why?
| | Female | 22 | 2019 | 61565 | 0.200 |
Why?
| | Detergents | 1 | 2001 | 44 | 0.200 |
Why?
| | Cytological Techniques | 1 | 2001 | 24 | 0.200 |
Why?
| | Histamine | 3 | 2012 | 65 | 0.200 |
Why?
| | Adult | 16 | 2015 | 31512 | 0.200 |
Why?
| | Sesamum | 1 | 2020 | 5 | 0.190 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 3 | 1991 | 34 | 0.190 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2001 | 71 | 0.190 |
Why?
| | Middle Aged | 13 | 2015 | 27617 | 0.190 |
Why?
| | Antibodies, Monoclonal | 2 | 2019 | 1284 | 0.190 |
Why?
| | Ethnopharmacology | 1 | 2000 | 1 | 0.190 |
Why?
| | Drugs, Chinese Herbal | 1 | 2000 | 14 | 0.190 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 94 | 0.190 |
Why?
| | Antigens | 3 | 1996 | 320 | 0.190 |
Why?
| | Pneumonia | 1 | 2006 | 592 | 0.190 |
Why?
| | Cell Membrane | 5 | 1995 | 710 | 0.180 |
Why?
| | Phosphoenolpyruvate | 3 | 1995 | 3 | 0.180 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2007 | 1171 | 0.180 |
Why?
| | Immunoblotting | 2 | 2011 | 307 | 0.180 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2001 | 298 | 0.180 |
Why?
| | Histocompatibility Antigens | 2 | 2013 | 102 | 0.180 |
Why?
| | Enzyme Activation | 6 | 2001 | 828 | 0.180 |
Why?
| | Nonprescription Drugs | 1 | 2000 | 67 | 0.180 |
Why?
| | Monocytes | 2 | 2007 | 513 | 0.180 |
Why?
| | Inflammation | 3 | 2007 | 2566 | 0.180 |
Why?
| | Adhesins, Escherichia coli | 1 | 1999 | 1 | 0.170 |
Why?
| | Mycoses | 1 | 2000 | 69 | 0.170 |
Why?
| | Fimbriae Proteins | 1 | 1999 | 15 | 0.170 |
Why?
| | Gastrointestinal Tract | 1 | 2021 | 175 | 0.170 |
Why?
| | Adhesins, Bacterial | 1 | 1999 | 36 | 0.170 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 2 | 2009 | 106 | 0.160 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2009 | 146 | 0.160 |
Why?
| | Awards and Prizes | 1 | 2018 | 57 | 0.160 |
Why?
| | History, 21st Century | 1 | 2018 | 170 | 0.160 |
Why?
| | Sinusitis | 1 | 2000 | 175 | 0.150 |
Why?
| | Phosphocreatine | 2 | 1995 | 37 | 0.150 |
Why?
| | History, 20th Century | 1 | 2018 | 281 | 0.150 |
Why?
| | Binding Sites | 2 | 2016 | 1224 | 0.150 |
Why?
| | Administration, Oral | 1 | 2019 | 756 | 0.150 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1997 | 37 | 0.150 |
Why?
| | Male | 14 | 2019 | 57801 | 0.150 |
Why?
| | Molecular Mimicry | 1 | 2017 | 40 | 0.150 |
Why?
| | Adolescent | 9 | 2019 | 18480 | 0.150 |
Why?
| | Calcimycin | 1 | 1996 | 57 | 0.150 |
Why?
| | Skin | 1 | 2021 | 657 | 0.150 |
Why?
| | Biomarkers | 2 | 2018 | 3588 | 0.140 |
Why?
| | Consensus Sequence | 1 | 2016 | 70 | 0.140 |
Why?
| | Cell Surface Display Techniques | 1 | 2016 | 10 | 0.140 |
Why?
| | Arachidonic Acid | 1 | 1996 | 122 | 0.140 |
Why?
| | Immunophenotyping | 2 | 2016 | 278 | 0.140 |
Why?
| | Leukocyte Common Antigens | 1 | 2016 | 76 | 0.140 |
Why?
| | Child | 10 | 2015 | 19129 | 0.140 |
Why?
| | Magnesium | 2 | 1993 | 150 | 0.140 |
Why?
| | Chemokine CCL2 | 1 | 2016 | 126 | 0.140 |
Why?
| | Bacteriophages | 1 | 2017 | 76 | 0.130 |
Why?
| | B-Lymphocyte Subsets | 1 | 2016 | 66 | 0.130 |
Why?
| | Adoptive Transfer | 1 | 2016 | 204 | 0.130 |
Why?
| | Cytokines | 5 | 2018 | 1900 | 0.130 |
Why?
| | Mice, Inbred BALB C | 3 | 2006 | 1206 | 0.130 |
Why?
| | Protein Array Analysis | 1 | 2015 | 63 | 0.130 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2013 | 140 | 0.130 |
Why?
| | Chromatography, Liquid | 2 | 2023 | 355 | 0.130 |
Why?
| | Lung Transplantation | 1 | 1997 | 263 | 0.130 |
Why?
| | Prostaglandin D2 | 3 | 2006 | 23 | 0.130 |
Why?
| | Tryptases | 2 | 2012 | 10 | 0.120 |
Why?
| | gamma-Tocopherol | 1 | 2014 | 4 | 0.120 |
Why?
| | Antigens, Dermatophagoides | 1 | 2014 | 15 | 0.120 |
Why?
| | Cyclooxygenase 2 | 2 | 2006 | 168 | 0.120 |
Why?
| | Tandem Mass Spectrometry | 2 | 2023 | 421 | 0.120 |
Why?
| | Macrophages | 1 | 2001 | 1324 | 0.120 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2013 | 245 | 0.120 |
Why?
| | Vitamin E | 1 | 2014 | 116 | 0.120 |
Why?
| | Genes, fos | 1 | 1993 | 36 | 0.120 |
Why?
| | Cats | 2 | 2004 | 205 | 0.120 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2006 | 613 | 0.110 |
Why?
| | Cluster Analysis | 1 | 2015 | 481 | 0.110 |
Why?
| | Headache | 1 | 2014 | 128 | 0.110 |
Why?
| | Asthma | 1 | 2006 | 2158 | 0.110 |
Why?
| | Pichia | 1 | 2012 | 20 | 0.110 |
Why?
| | Proteomics | 1 | 2018 | 876 | 0.110 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 332 | 0.110 |
Why?
| | Albumins | 2 | 2023 | 100 | 0.110 |
Why?
| | Mutant Proteins | 1 | 2012 | 100 | 0.100 |
Why?
| | Transfection | 2 | 2007 | 888 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 982 | 0.100 |
Why?
| | Complex Mixtures | 1 | 2011 | 13 | 0.100 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 736 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 3 | 2010 | 2275 | 0.100 |
Why?
| | Blotting, Western | 2 | 2007 | 1194 | 0.100 |
Why?
| | Histamine Release | 3 | 2013 | 22 | 0.100 |
Why?
| | Case-Control Studies | 1 | 2018 | 3171 | 0.100 |
Why?
| | Algorithms | 2 | 2008 | 1541 | 0.100 |
Why?
| | Lipopolysaccharides | 2 | 2007 | 870 | 0.090 |
Why?
| | Phosphoric Diester Hydrolases | 2 | 2006 | 45 | 0.090 |
Why?
| | Pharmacists | 1 | 2013 | 238 | 0.090 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2003 | 61 | 0.090 |
Why?
| | HLA-DRB1 Chains | 1 | 2010 | 97 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2007 | 827 | 0.090 |
Why?
| | Antibody Formation | 1 | 2011 | 276 | 0.090 |
Why?
| | Aged | 4 | 2015 | 19657 | 0.090 |
Why?
| | Respiratory Tract Infections | 1 | 2014 | 331 | 0.090 |
Why?
| | Autoantibodies | 2 | 2009 | 1335 | 0.090 |
Why?
| | Medical Records | 1 | 2010 | 163 | 0.090 |
Why?
| | Siblings | 1 | 2010 | 235 | 0.090 |
Why?
| | Chromatography, Gel | 1 | 2009 | 133 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 1945 | 0.090 |
Why?
| | Young Adult | 3 | 2015 | 10793 | 0.090 |
Why?
| | Gene Frequency | 1 | 2010 | 513 | 0.090 |
Why?
| | Ovalbumin | 2 | 2006 | 165 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 969 | 0.090 |
Why?
| | Dermatitis, Allergic Contact | 1 | 2009 | 60 | 0.080 |
Why?
| | Molecular Weight | 1 | 2009 | 343 | 0.080 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2010 | 355 | 0.080 |
Why?
| | Haplotypes | 1 | 2010 | 473 | 0.080 |
Why?
| | Infant | 5 | 2013 | 8293 | 0.080 |
Why?
| | Diphenhydramine | 1 | 2008 | 29 | 0.080 |
Why?
| | Cytoplasm | 1 | 1989 | 269 | 0.080 |
Why?
| | Histamine H1 Antagonists | 1 | 2008 | 33 | 0.080 |
Why?
| | Phenotype | 1 | 2016 | 3003 | 0.080 |
Why?
| | Th2 Cells | 2 | 2006 | 164 | 0.080 |
Why?
| | Escherichia coli | 1 | 2012 | 758 | 0.080 |
Why?
| | Administration, Intranasal | 1 | 2008 | 79 | 0.080 |
Why?
| | Membrane Proteins | 2 | 2005 | 1055 | 0.080 |
Why?
| | Immunotherapy | 2 | 2009 | 493 | 0.080 |
Why?
| | United States | 4 | 2018 | 12555 | 0.080 |
Why?
| | Epinephrine | 1 | 2008 | 167 | 0.080 |
Why?
| | Interleukin-4 | 1 | 2008 | 215 | 0.070 |
Why?
| | Abscess | 1 | 1987 | 75 | 0.070 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2007 | 26 | 0.070 |
Why?
| | Lysine | 2 | 2001 | 248 | 0.070 |
Why?
| | HMGB1 Protein | 1 | 2007 | 49 | 0.070 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2007 | 74 | 0.070 |
Why?
| | Polysaccharides, Bacterial | 1 | 2007 | 69 | 0.070 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2007 | 76 | 0.070 |
Why?
| | Transcription Factor RelA | 1 | 2007 | 82 | 0.070 |
Why?
| | Immunoprecipitation | 1 | 2007 | 161 | 0.070 |
Why?
| | Cyclooxygenase 1 | 1 | 2006 | 22 | 0.070 |
Why?
| | ZAP-70 Protein-Tyrosine Kinase | 1 | 2006 | 8 | 0.070 |
Why?
| | Nigella sativa | 1 | 2006 | 1 | 0.070 |
Why?
| | Goblet Cells | 1 | 2006 | 17 | 0.070 |
Why?
| | Pyrophosphatases | 1 | 2006 | 22 | 0.070 |
Why?
| | Diagnosis, Differential | 3 | 2008 | 1384 | 0.070 |
Why?
| | Endotoxins | 1 | 2007 | 234 | 0.070 |
Why?
| | Staphylococcal Infections | 2 | 1987 | 346 | 0.070 |
Why?
| | Environmental Exposure | 2 | 2009 | 405 | 0.070 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2005 | 15 | 0.070 |
Why?
| | Dermatitis, Atopic | 1 | 2009 | 332 | 0.070 |
Why?
| | Bronchial Hyperreactivity | 1 | 2006 | 95 | 0.070 |
Why?
| | Plasmids | 1 | 2007 | 355 | 0.070 |
Why?
| | Serum | 1 | 2006 | 63 | 0.070 |
Why?
| | Databases, Factual | 1 | 2011 | 1231 | 0.070 |
Why?
| | Alopecia Areata | 1 | 2005 | 11 | 0.070 |
Why?
| | Immunochemistry | 1 | 2005 | 13 | 0.070 |
Why?
| | Thyroid Hormones | 1 | 2005 | 55 | 0.070 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 2851 | 0.070 |
Why?
| | Haptens | 2 | 1996 | 22 | 0.070 |
Why?
| | Leukocyte Count | 1 | 2006 | 305 | 0.070 |
Why?
| | Toll-Like Receptors | 1 | 2006 | 167 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 940 | 0.060 |
Why?
| | Staphylococcus aureus | 2 | 1987 | 394 | 0.060 |
Why?
| | Vitiligo | 1 | 2005 | 75 | 0.060 |
Why?
| | Biological Assay | 1 | 2005 | 122 | 0.060 |
Why?
| | Physicians | 1 | 2013 | 794 | 0.060 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2001 | 407 | 0.060 |
Why?
| | Antibodies, Bacterial | 1 | 1985 | 126 | 0.060 |
Why?
| | Immunoglobulin A | 1 | 1985 | 174 | 0.060 |
Why?
| | Sequence Alignment | 2 | 2014 | 336 | 0.060 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2003 | 20 | 0.060 |
Why?
| | Immunologic Techniques | 1 | 2003 | 40 | 0.060 |
Why?
| | Vaccines | 1 | 2008 | 380 | 0.060 |
Why?
| | Lung | 2 | 2006 | 3664 | 0.060 |
Why?
| | Nut Hypersensitivity | 1 | 2023 | 9 | 0.060 |
Why?
| | Antibody Specificity | 2 | 2003 | 184 | 0.060 |
Why?
| | Up-Regulation | 1 | 2006 | 872 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2674 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2006 | 827 | 0.050 |
Why?
| | Cell Count | 2 | 2021 | 315 | 0.050 |
Why?
| | Promoter Regions, Genetic | 1 | 2007 | 1158 | 0.050 |
Why?
| | Signal Transduction | 4 | 2007 | 4709 | 0.050 |
Why?
| | Hypereosinophilic Syndrome | 1 | 2021 | 9 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2014 | 9342 | 0.050 |
Why?
| | MAP Kinase Kinase Kinase 3 | 1 | 2001 | 3 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 10 | 1 | 2001 | 3 | 0.050 |
Why?
| | Octoxynol | 1 | 2001 | 12 | 0.050 |
Why?
| | MAP Kinase Kinase Kinase 2 | 1 | 2001 | 12 | 0.050 |
Why?
| | Mastocytosis | 1 | 2021 | 12 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 8 | 1 | 2001 | 16 | 0.050 |
Why?
| | Reproducibility of Results | 1 | 2009 | 2874 | 0.050 |
Why?
| | Precipitin Tests | 1 | 2001 | 93 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 9 | 1 | 2001 | 18 | 0.050 |
Why?
| | Immune Sera | 1 | 2001 | 82 | 0.050 |
Why?
| | Time Factors | 2 | 2011 | 6412 | 0.050 |
Why?
| | Enzyme Stability | 1 | 2001 | 75 | 0.050 |
Why?
| | T-Lymphocytes | 2 | 2018 | 1774 | 0.050 |
Why?
| | Biopsy | 2 | 2021 | 1079 | 0.050 |
Why?
| | Hydrolysis | 2 | 1993 | 176 | 0.050 |
Why?
| | Valine | 1 | 2001 | 77 | 0.050 |
Why?
| | Exocytosis | 2 | 1993 | 88 | 0.050 |
Why?
| | Shock, Septic | 1 | 1983 | 187 | 0.050 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2001 | 155 | 0.050 |
Why?
| | Bacterial Infections | 1 | 1983 | 227 | 0.050 |
Why?
| | Gastritis | 1 | 2021 | 82 | 0.050 |
Why?
| | Transcription, Genetic | 1 | 2007 | 1323 | 0.050 |
Why?
| | Serine | 1 | 2001 | 138 | 0.050 |
Why?
| | Leukemia | 1 | 1983 | 208 | 0.050 |
Why?
| | Enteritis | 1 | 2021 | 78 | 0.050 |
Why?
| | Medicine, Traditional | 1 | 2000 | 23 | 0.050 |
Why?
| | Catalysis | 1 | 2001 | 295 | 0.050 |
Why?
| | Radioallergosorbent Test | 1 | 2000 | 4 | 0.050 |
Why?
| | Environmental Illness | 1 | 2000 | 2 | 0.050 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2001 | 363 | 0.050 |
Why?
| | Hypersensitivity, Delayed | 1 | 2000 | 52 | 0.050 |
Why?
| | Protein Domains | 1 | 2021 | 212 | 0.050 |
Why?
| | Growth Hormone | 1 | 1980 | 108 | 0.040 |
Why?
| | Interleukin-3 | 2 | 1989 | 25 | 0.040 |
Why?
| | Eosinophilia | 1 | 2021 | 184 | 0.040 |
Why?
| | Mannose | 1 | 1999 | 21 | 0.040 |
Why?
| | Calcium | 3 | 1991 | 1169 | 0.040 |
Why?
| | Prevalence | 1 | 2005 | 2326 | 0.040 |
Why?
| | Serotonin | 1 | 2001 | 309 | 0.040 |
Why?
| | Ribosomes | 1 | 1980 | 142 | 0.040 |
Why?
| | Muscles | 1 | 1980 | 333 | 0.040 |
Why?
| | Mice, Inbred C3H | 1 | 1999 | 250 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2003 | 1795 | 0.040 |
Why?
| | Drug Prescriptions | 1 | 2000 | 248 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 4708 | 0.040 |
Why?
| | Eosinophilic Esophagitis | 1 | 2021 | 308 | 0.040 |
Why?
| | Leukotriene C4 | 1 | 1996 | 13 | 0.040 |
Why?
| | Phosphorylation | 1 | 2001 | 1633 | 0.040 |
Why?
| | Antibody Affinity | 1 | 1996 | 55 | 0.040 |
Why?
| | Latex | 1 | 1996 | 12 | 0.040 |
Why?
| | Rubber | 1 | 1996 | 8 | 0.040 |
Why?
| | Polyethylene Glycols | 1 | 2001 | 578 | 0.030 |
Why?
| | Double-Blind Method | 3 | 2006 | 1687 | 0.030 |
Why?
| | Adenosine-5'-(N-ethylcarboxamide) | 1 | 1995 | 9 | 0.030 |
Why?
| | Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 1995 | 18 | 0.030 |
Why?
| | Cell Fractionation | 2 | 1989 | 53 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2018 | 502 | 0.030 |
Why?
| | Vanadates | 1 | 1995 | 29 | 0.030 |
Why?
| | Oligonucleotides | 1 | 1996 | 140 | 0.030 |
Why?
| | Drug Interactions | 1 | 1996 | 352 | 0.030 |
Why?
| | Hydroxylation | 1 | 2014 | 26 | 0.030 |
Why?
| | Cell Membrane Permeability | 1 | 1995 | 88 | 0.030 |
Why?
| | Leukotriene D4 | 1 | 2014 | 1 | 0.030 |
Why?
| | Dose-Response Relationship, Immunologic | 2 | 2004 | 82 | 0.030 |
Why?
| | Receptor Aggregation | 1 | 1993 | 8 | 0.030 |
Why?
| | Dinitrobenzenes | 1 | 1993 | 6 | 0.030 |
Why?
| | Phosphotyrosine | 1 | 1993 | 37 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2001 | 1753 | 0.030 |
Why?
| | Recombinant Proteins | 3 | 2012 | 1308 | 0.030 |
Why?
| | Adenosine | 1 | 1995 | 211 | 0.030 |
Why?
| | Mass Vaccination | 1 | 2013 | 17 | 0.030 |
Why?
| | Tyrosine | 1 | 1993 | 233 | 0.030 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2013 | 69 | 0.030 |
Why?
| | Permeability | 1 | 1993 | 156 | 0.030 |
Why?
| | Leukocytes | 1 | 1974 | 290 | 0.030 |
Why?
| | Receptors, Interleukin-2 | 2 | 2004 | 65 | 0.030 |
Why?
| | Circular Dichroism | 1 | 2012 | 139 | 0.030 |
Why?
| | Air Pollutants | 1 | 1996 | 316 | 0.030 |
Why?
| | Clone Cells | 1 | 2012 | 248 | 0.030 |
Why?
| | Protein Kinase C | 1 | 1993 | 297 | 0.030 |
Why?
| | Phosphatidylinositol Diacylglycerol-Lyase | 1 | 1991 | 3 | 0.030 |
Why?
| | Phosphoinositide Phospholipase C | 1 | 1991 | 4 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 1993 | 1094 | 0.030 |
Why?
| | Phosphoproteins | 1 | 1993 | 308 | 0.020 |
Why?
| | Point Mutation | 1 | 2012 | 228 | 0.020 |
Why?
| | Subcellular Fractions | 1 | 1991 | 84 | 0.020 |
Why?
| | Kinetics | 1 | 2014 | 1624 | 0.020 |
Why?
| | Protein Folding | 1 | 2012 | 250 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 1991 | 413 | 0.020 |
Why?
| | DNA | 2 | 1996 | 1388 | 0.020 |
Why?
| | Pruritus | 1 | 2010 | 60 | 0.020 |
Why?
| | Flow Cytometry | 2 | 2004 | 1085 | 0.020 |
Why?
| | Pemphigus | 1 | 2009 | 8 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 1989 | 9 | 0.020 |
Why?
| | Rosette Formation | 1 | 1989 | 16 | 0.020 |
Why?
| | Energy Metabolism | 1 | 1995 | 767 | 0.020 |
Why?
| | Psoriasis | 1 | 2009 | 76 | 0.020 |
Why?
| | Thyroxine | 1 | 2009 | 63 | 0.020 |
Why?
| | Extracellular Space | 1 | 1989 | 127 | 0.020 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 1988 | 35 | 0.020 |
Why?
| | Adaptive Immunity | 1 | 2009 | 161 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 1781 | 0.020 |
Why?
| | Vasoconstrictor Agents | 1 | 2008 | 122 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2010 | 599 | 0.020 |
Why?
| | Influenza, Human | 1 | 2013 | 554 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2010 | 749 | 0.020 |
Why?
| | Body Fluid Compartments | 1 | 1987 | 6 | 0.020 |
Why?
| | Ribonucleases | 2 | 1980 | 53 | 0.020 |
Why?
| | Metabolic Clearance Rate | 1 | 1987 | 113 | 0.020 |
Why?
| | Dermatitis, Contact | 1 | 1987 | 20 | 0.020 |
Why?
| | Psychometrics | 1 | 2010 | 631 | 0.020 |
Why?
| | Rhinometry, Acoustic | 1 | 2006 | 1 | 0.020 |
Why?
| | IgG Deficiency | 1 | 2006 | 8 | 0.020 |
Why?
| | Necrosis | 1 | 2007 | 230 | 0.020 |
Why?
| | Bronchial Provocation Tests | 1 | 2006 | 54 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2007 | 249 | 0.020 |
Why?
| | Postoperative Complications | 1 | 1997 | 2235 | 0.020 |
Why?
| | Cells, Cultured | 3 | 2007 | 4077 | 0.020 |
Why?
| | Serine Endopeptidases | 1 | 2006 | 105 | 0.020 |
Why?
| | Dinoprostone | 1 | 2006 | 193 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 965 | 0.020 |
Why?
| | Immunoglobulin A, Secretory | 1 | 1985 | 11 | 0.020 |
Why?
| | Immunoglobulin D | 1 | 1985 | 28 | 0.020 |
Why?
| | Haemophilus Infections | 1 | 1985 | 31 | 0.020 |
Why?
| | Granulomatous Disease, Chronic | 1 | 1985 | 61 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2006 | 456 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2009 | 745 | 0.010 |
Why?
| | Immunoglobulin M | 1 | 1985 | 253 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2007 | 688 | 0.010 |
Why?
| | Disease Progression | 1 | 2010 | 2490 | 0.010 |
Why?
| | Agranulocytosis | 1 | 1983 | 31 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1999 | 3360 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2013 | 5255 | 0.010 |
Why?
| | Peritonitis | 1 | 1983 | 79 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 6561 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2004 | 462 | 0.010 |
Why?
| | Hypophysectomy | 1 | 1980 | 15 | 0.010 |
Why?
| | Puromycin | 1 | 1980 | 11 | 0.010 |
Why?
| | Centrifugation, Density Gradient | 1 | 1980 | 41 | 0.010 |
Why?
| | Peptide Biosynthesis | 1 | 1980 | 14 | 0.010 |
Why?
| | Thy-1 Antigens | 1 | 1999 | 11 | 0.010 |
Why?
| | Concanavalin A | 1 | 1999 | 74 | 0.010 |
Why?
| | CD28 Antigens | 1 | 1999 | 46 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2008 | 4596 | 0.010 |
Why?
| | Leucine | 1 | 1980 | 117 | 0.010 |
Why?
| | Mitogens | 1 | 1999 | 57 | 0.010 |
Why?
| | Rats, Inbred F344 | 1 | 1999 | 245 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2003 | 984 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 2445 | 0.010 |
Why?
| | Serotonin Antagonists | 1 | 1996 | 31 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1996 | 205 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1999 | 632 | 0.010 |
Why?
| | Photomicrography | 1 | 1974 | 6 | 0.010 |
Why?
| | Ligands | 1 | 1996 | 567 | 0.010 |
Why?
| | Nucleic Acid Denaturation | 1 | 1974 | 30 | 0.010 |
Why?
| | Methods | 1 | 1974 | 67 | 0.010 |
Why?
| | Aspergillus | 1 | 1974 | 18 | 0.010 |
Why?
| | Deoxyribonucleases | 1 | 1974 | 21 | 0.010 |
Why?
| | Chromatography, Ion Exchange | 1 | 1974 | 51 | 0.010 |
Why?
| | Spectrophotometry | 1 | 1974 | 52 | 0.010 |
Why?
| | Histocytochemistry | 1 | 1974 | 82 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1974 | 182 | 0.010 |
Why?
| | Freezing | 1 | 1974 | 87 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1974 | 146 | 0.010 |
Why?
| | Nucleic Acid Conformation | 1 | 1996 | 670 | 0.010 |
Why?
| | DNA, Single-Stranded | 1 | 1974 | 114 | 0.010 |
Why?
| | Base Sequence | 1 | 1996 | 2159 | 0.010 |
Why?
| | Hot Temperature | 1 | 1974 | 334 | 0.010 |
Why?
| | Pancreas | 1 | 1974 | 282 | 0.010 |
Why?
| | Chromatin | 1 | 1974 | 441 | 0.010 |
Why?
| | RNA | 1 | 1996 | 833 | 0.010 |
Why?
| | Interphase | 1 | 1989 | 30 | 0.010 |
Why?
| | Ethanol | 1 | 1974 | 575 | 0.010 |
Why?
| | Peptide Hydrolases | 1 | 1989 | 108 | 0.010 |
Why?
| | Cell Division | 1 | 1989 | 776 | 0.000 |
Why?
| | Extracellular Matrix | 1 | 1989 | 446 | 0.000 |
Why?
|
|
Dreskin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|